Skip to main content

Table 2 Prevalence of metabolic syndrome and its components according to criteria, by sex [% and (95%CI)]

From: Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions

 

Overall

Men

Women

P value

  

(N= 1240)

(N = 628)

(N=612)

Abnormal waist circumference ǂ

20.9 (18.6-23.2)

8.1 (6.0-10.2)

34.0 (30.2-37.8)

<0.001

Abnormal waist circumference ǂǂ

46.4 (43.6-49.2)

34.7 (31.0-38.4)

58.3 (54.4-62.2)

<0.001

Blood pressure ≥130/85 mmHg*

28.3 (25.8-30.8)

31.7 (28.1-35.3)

24.8 (21.4-28.2)

0.007

HDL-Cholesterol <40 or <50 mg/dl*

38.8 (36.1-41.5)

33.8 (30.1-37.5)

44.0 (40.1-47.9)

<0.001

Triglycerides ≥150 mg/dl*

35.9 (33.2-38.6)

41.8 (37.9-45.7)

29.9 (26.3-33.5)

<0.001

Fasting glucose ≥100 mg/d*

15.1 (13.1-17.1)

15.1 (12.3-17.9)

15.0 (12.2-17.8)

0.9

Prevalence of metabolic syndrome

    

 NCEP-ATPIII

17.2 (12.1-22.3)

15.2 (7.9-22.5)

19.2 (12.1-26.3)

0.06

 IDF

22.1 (17.2-27.0)

20.7 (13.7-27.7)

23.5 (16,5-30.5)

0.2

 AHA/NHLBI

24.7 (19.8-29.5)

24.6 (17.7-31.4)

24.8 (17.9-31.7)

0.9

  1. * Abnormal values or on pharmacological treatment.
  2. ǂCutoffs by sex: NCEP-ATPIII ≥ 102 cm in men, ≥ 88 cm in women.
  3. ǂǂCutoffs by sex: IDF and AHA/NHLBI definition ≥ 90 cm in men, ≥ 80 cm in women as the thresholds for South Americans.